NCT04765020 Cardiorespiratory Fitness in Children and Adolescents After Cancer Treatment.
| NCT ID | NCT04765020 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Universität Duisburg-Essen |
| Condition | All Types of Pediatric Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2021-06-21 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 56 participants in total. It began in 2021-06-21 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The POWER-study is a two-arm exercise intervention study for pediatric patients following acute cancer treatment. This clinical trial will investigate the effects of a 12-week moderate to high-intensity exercise program on cardiorespiratory fitness in children and adolescents beginning 6 weeks after completion of acute cancer treatment.
Eligibility Criteria
Inclusion Criteria: * Children and adolescents between 7 and 23 years of age * Completion of acute cancer treatment and receiving follow-up care in Krefeld (Helios Hospital Krefeld) * 6 weeks post cancer-treatment * Signed informed consent (Parents and Patient) Exclusion Criteria: * \<7 years of age, \>23 years of age * Medical condition that limits participation in one of the study arms * Inability to follow the training-protocol * Inability to carry out the spiroergometry on a cycle ergometer
Contact & Investigator
Miriam Götte, Phd
PRINCIPAL INVESTIGATOR
University Hospital, Essen
Frequently Asked Questions
Who can join the NCT04765020 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 23 Years, studying All Types of Pediatric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04765020 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT04765020 currently recruiting?
Yes, NCT04765020 is actively recruiting participants. Contact the research team at sandra.goertz@helios-gesundheit.de for enrollment information.
Where is the NCT04765020 trial being conducted?
This trial is being conducted at Krefeld, Germany.
Who is sponsoring the NCT04765020 clinical trial?
NCT04765020 is sponsored by Universität Duisburg-Essen. The principal investigator is Miriam Götte, Phd at University Hospital, Essen. The trial plans to enroll 56 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.